Is Acurx Pharmaceuticals, Inc. (ACXP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 107.8% / 30% | 1.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 107.8% / 33% | 1.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 96.1% / 33% | 1.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 107.8% / 33% | 1.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 96.1% / 33% | 1.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -270.8% | |
| Return on Assets (ROA) | -87.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Current Ratio | 3.2 |
| Total Assets | $8M |
Price & Trading
| Last Close | $4.01 |
| 50-Day MA | $2.81 |
| 200-Day MA | $4.95 |
| Avg Volume | 3.2M |
| Beta | -1.2 |
|
52-Week Range
$1.33
| |
About Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Acurx Pharmaceuticals, Inc. (ACXP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Acurx Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Acurx Pharmaceuticals, Inc.'s debt ratio?
Acurx Pharmaceuticals, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Acurx Pharmaceuticals, Inc.'s key financial metrics?
Acurx Pharmaceuticals, Inc. has a market capitalization of $11M. Return on equity stands at -270.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.